Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [ 177 Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure-Preliminary Evidence of Pilot Experience

Well-received strong efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) does not prevent patients from either early or eventual disease progression under this treatment. In this study, we investigated co-medication with enzalutamide as a potential re-sensitizer...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-05, Vol.14 (11), p.2691
Main Authors: Rosar, Florian, Bader, Hanna, Bartholomä, Mark, Maus, Stephan, Burgard, Caroline, Linxweiler, Johannes, Khreish, Fadi, Ezziddin, Samer
Format: Article
Language:English
Subjects:
Androgens
Anemia
Antigens
Communication
Consent
Metastasis
Patients
Prostate
Prostate cancer
Prostate-specific antigen
Remission
Remission (Medicine)
Review boards
Thrombocytopenia
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Well-received strong efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) does not prevent patients from either early or eventual disease progression under this treatment. In this study, we investigated co-medication with enzalutamide as a potential re-sensitizer for PSMA-RLT in patients with imminent treatment failure on standard Lu-based PSMA-RLT. Ten mCRPC patients who exhibited an insufficient response to conventional [ Lu]Lu-PSMA-617 RLT received oral medication of enzalutamide 160 mg/d as an adjunct to continued PSMA-RLT. Prostate-specific antigen (PSA) and standard toxicity screening lab work-up were performed to assess the treatment efficacy and safety in these individuals. The mean PSA increase under PSMA-RLT before starting the re-sensitizing procedure was 22.4 ± 26.5%. After the introduction of enzalutamide medication, all patients experienced a PSA decrease, -43.4 ± 20.0% and -48.2 ± 39.0%, after one and two cycles of enzalutamide-augmented PSMA-RLT, respectively. A total of 70% of patients (7/10) experienced partial remission, with a median best PSA response of -62%. Moreover, 5/6 enzalutamide-naïve patients and 2/4 patients who had previously failed enzalutamide exhibited a partial remission. There was no relevant enzalutamide-induced toxicity observed in this small cohort. This pilot experience suggests the synergistic potential of adding enzalutamide to PSMA-RLT derived from the intra-individual comparison of Lu-based PSMA-RLT ± enzalutamide.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14112691